Clinical efficacy of CARTOSound-guided radiofrequency ablation for hypertrophic obstructive cardiomyopathy

Zhouqin JIANG; Maoqin SHU; Hong CHAI; Shengrong DENG; Xinghua CHEN; Hao GAO; Yang ZHOU

doi:10.16016/j.1000-5404.202009168

您当前的位置：

首页 >

文章列表页 >

Clinical efficacy of CARTOSound-guided radiofrequency ablation for hypertrophic obstructive cardiomyopathy

Clinical Medicine | 更新时间：2026-01-09

- Clinical efficacy of CARTOSound-guided radiofrequency ablation for hypertrophic obstructive cardiomyopathy
- Journal of Third Military Medical University Vol. 43, Issue 8, Pages: 736-740(2021)
- 作者机构：
  
  400038 重庆，陆军军医大学(第三军医大学)第一附属医院心血管内科
- 作者简介：
- 基金信息：
  
  the Project of the First Affiliated Hospital of Third Military Medical University(SWH2016JSTSYB-4)
- DOI：10.16016/j.1000-5404.202009168
  CLC： R445.1;R540.46;R542.2
- Received：20 September 2020，
  
  Revised：2020-12-09，
  
  Published：30 April 2021
- 稿件说明：
移动端阅览
Zhouqin JIANG, Maoqin SHU, Hong CHAI, et al. Clinical efficacy of CARTOSound-guided radiofrequency ablation for hypertrophic obstructive cardiomyopathy[J]. Journal of Third Military Medical University, 2021, 43(8): 736-740.
DOI：

Zhouqin JIANG, Maoqin SHU, Hong CHAI, et al. Clinical efficacy of CARTOSound-guided radiofrequency ablation for hypertrophic obstructive cardiomyopathy[J]. Journal of Third Military Medical University, 2021, 43(8): 736-740. DOI： 10.16016/j.1000-5404.202009168.

摘要

目的

探讨CARTOSound引导下射频消融对肥厚型梗阻性心肌病患者的临床疗效。

方法

连续入选2019年6-12月在本院心血管内科就诊的经超声心动图证实存在收缩期二尖瓣前叶前向运动(systolic anterior motion

SAM)现象的肥厚型梗阻性心肌病患者，就其临床特征、消融策略及消融效果进行回顾性分析。根据消融效果不同分为反应组和非反应组，分析影响消融效果的因素。

结果

共入选1

1例，其中男性3例，女性8例，年龄44~77(58.36±10.82)岁，病史6个月至2年，患者经消融后腔内即刻静息跨左心室流出道压力阶差(20.00±31.12 mmHg

57.09±33.44 mmHg，

=0.01)及早搏刺激后跨左心室流出道压力阶差(24.09±19.34 mmHg

139.60±44.52 mmHg，

0.01)均明显下降，随访3个月后心脏超声提示室间隔厚度(18.15±92.84 mm)较术前无明显差异(19.50±2.67 mm，

=0.35)，跨左心室流出道压力阶差较术前有所下降，但无统计学差异(71.09±31.40 mmHg

52.38±35.76 mmHg，

=0.28)，术后6个月随访结果相似，但患者NYHA明显改善(1.64±0.15

2.36±0.20，

0.01)。与非反应组(5例)比较，反应组(6例)患者有室间隔厚度更薄、左心室直径更小、BNP更低的趋势。

结论

CARTOsound引导下射频消融治疗肥厚型梗阻性心肌病患者可改善心功能，短期内可缓解左心室流出道梗阻。

Abstract

Objective

To investigate the clinical efficacy of CARTOSound-guided radiofrequency ablation on hypertrophic obstructive cardiomyopathy.

Methods

The consecutive patients with hypertrophic obstructive cardiomyopathy accompanied with systolic anterior mitral valve movement (SAM) confirmed by echocardiography in our hospital from June to December 2019 were enrolled in this study. A retrospective study was carried out on the clinical features

ablative strategies and ablative effects. According to the ablation effects

the patients were divided into response group and non-response group

and the factors affecting the ablation effect were analyzed.

Results

There were 11 enrolled patients (3 males and 8 females

aged 58.36±10.82 years

ranging from 44 to 77 years) with a history of hypertrophic obstructive cardiomyopathy for 6 months to 2 years. The left ventricular outflow tract gradient (LVOTG) at rest (20.00±31.12

57.09±33.44 mmHg

=0.01) and at ventricular premature beat stimulation (24.09±19.34

139.60±44.52 mmHg

0.01) were significantly decreased immediately in the patients after ablation. After 3 month

s follow-up

echocardiography showed no significant difference in ventricular septal thickness compared with that before ablation (18.15±92.84

19.50±2.67 mm

=0.35)

and the LVOGT was decreased slightly and had no statistical difference (71.09±31.40

52.38±35.76 mmHg

=0.28). Similiar results were seen after 6 months follow-up

but the NYHA grade was significantly improved (1.64±0.15

2.36±0.20

0.01). The ventricular septal thickness was thinner

the left ventricular diameter was smaller

and B-type natriuretic peptide (BNP) level was lower in the response group (

=6) than those in the non-response group (

=5).

Conclusion

CARTOsound-guided radiofrequency ablation can improve cardiac function and alleviate short-term left ventricular outflow tract obstruction in the patients with hypertrophic obstructive cardiomyopathy.

关键词

Keywords

references

SPAZIANO M, SAWAYA F. J, LEFEVRE T. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: indications, technical aspects, and clinical outcomes[J]. J Invasive Cardiol, 2017, 29(12): 404-410. DOI: 10.1016/S0140-6736(16)31321-6.

MARON M S, OLIVOTTO I, ZENOVICH A G, et al . Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction[J ] . Circulation, 2006, 114(21): 2232-2239. DOI:10.1161/circulationaha.106.644682.

MARON M S, OLIVOTTO I, BETOCCHI S, et al . Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy[J ] . N Engl J Med, 2003, 348(4): 295-303. DOI:10.1056/nejmoa021332.

JENSEN M K, PRINZ C, HORSTKOTTE D, et al . Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile[J ] . Heart, 2013, 99(14): 1012-1017. DOI:10.1136/heartjnl-2012-303339.

LAWRENZ T B, BORCHERT C, LEUNER M, et al . Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months' follow-up in 19 patients[J ] . J Am Coll Cardiol, 2011, 57(5): 572-576. DOI: 10.1016/j.jacc.2010.07.055.

COOPER R M, SHAHZAD A, NEWTON J, et al . Intra-cardiac echocardiography in alcohol septal ablation: a prospective comparative study against trans-thoracic echocardiography[J ] . Echo Res Pract, 2015, 2(1): 9-17. DOI: 10.1530/erp-15-0002.

ELLIOTT P M, ANASTASAKIS A, BORGER M A, et al . 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)[J ] . Eur Heart J, 2014, 35(39): 2733-2779. DOI: 10.1093/eurheartj/ehu284.

SOLOMON Z, BRETON C, ROWIN E J, et al . Surgical approaches to hypertrophic obstructive cardiomyopathy[J ] . Semin Thorac Cardiovasc Surg, 2018, 30(2): 125-128. DOI: 10.1053/j.semtc vs .2018.02.034..

CALDERON-ROJAS R, NGUYEN A, NISHIMURA R A, et al . Is there referral bias in outcomes of septal myectomy for hypertrophic cardiomyopathy?[J ] . J Thorac Cardiovasc Surg, 2020. DOI: 10.1016/j.jtc vs .2020.08.118..

VESELKA J, ANAVEKAR N S, CHARRON P. Hypertrophic obstructive cardiomyopathy[J]. Lancet, 2017, 389(10075): 1253-1267. DOI:10.1016/s0140-6736(16)31321-6.

陈冉, 蒋志新, 单其俊. 室间隔射频消融术: 治疗梗阻性肥厚型心肌病的新选择[J]. 中华心血管病杂志, 2017, 45(3): 186-189. DOI: 10.3760/cma.j.issn.0253-3758.2017.03.004.

CHEN R, JIANG Z X, SHAN Q J. Radiofrequency ablation of the ventricular septum: a new option for the treatment of obstructive hypertrophic cardiomyopathy[J]. Chin J Cardiol, 2017, 45(3): 186-189. DOI: 10.3760/cma.j.issn.0253-3758.2017.03.004.

YANGH N, YANG Y, XUE Y H, et al . Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: A systematic review and meta-analysis[J ] . Clin Cardiol, 2020, 43(5): 450-458. DOI: 10.1002/clc.23341.

CHAN W, WILLIAMS L, KOTOWYCZ M A, et al . Angiographic and echocardiographic correlates of suitable septal perforators for alcohol septal ablation in hypertrophic obstructive cardiomyopathy[J ] . Can J Cardiol, 2014, 30(8): 912-919. DOI:10.1016/j.cjca.2014.04.008.

COOPER R M, SHAHZAD A, HASLETON J, et al . Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound©technology to guide ablation[J ] . Europace, 2016, 18(1): 113-120. DOI: 10.1093/europace/euv302.

LIU L W, LI J, ZUO L, et al . Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy[J ] . J Am Coll Cardiol, 2018, 72(16): 1898-1909. DOI:10.1016/j.jacc.2018.07.080.

LIU L, LIU B, LI J, et al . Percutaneous intramyocardial septal radiofrequency ablation of hypertrophic obstructive cardiomyopathy: a novel minimally invasive treatment for reduction of outflow tract obstruction[J ] . EuroIntervention, 2018, 13(18): e2112-e2113. DOI: 10.4244/EIJ-D-17-00657.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy of different treatments for progressive subdural effusion after decompressive craniectomy for craniocerebral injury

Decreasing amplitude of left ventricular outflow tract gradient and its influencing factors after alcohol septal ablation

Clinical efficacy and safety of ruxolitinib in treatment of chronic graft versus host disease

Laparoscopic hepatectomy versus radiofrequency ablation in treatment of recurrent hepatocellular carcinoma: a prospective randomized control study based on interim follow-up analysis

Clinical efficacy of high versus regular dose of ulinastatin combined with Xuebijing for treatment of sepsis

Related Author

Enren WANG

Jie ZHANG

Haibo LIU

Zhongxin YANG

Qiongfen WANG

Yingjun FAN

Yong ZHANG

Xiaoyan LIU

Related Institution

Department of Cardiology, Institute of Cardiology, Second Affiliated Hospital, Army Medical University(Third Military Medical University)

Institute of Hepatobiliary Surgery, First Affiliated Hospital, Army Medical University (Third Military Medical University)

Department of Cardiology, Affiliated Provincial Hospital of Anhui Medical University

Department of Cardiology, Third Affiliated Hospital of Bengbu Medical College, General Hospital of Wanbei Coal-Electricity Group

⁰